Solid Biosciences Inc. Contract with Customer, Liability, Noncurrent
Solid Biosciences Inc. (SLDB) had Contract with Customer, Liability, Noncurrent of $2.26 million as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2022-03-14
- 2021-09-30: Contract with Customer, Liability, Noncurrent $2.26M.
- 2021-06-30: Contract with Customer, Liability, Noncurrent $4.31M.
- 2021-03-31: Contract with Customer, Liability, Noncurrent $7.00M.
- 2020-12-31: Contract with Customer, Liability, Noncurrent $10.36M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2021-09-30 | $2.26M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $4.31M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $7.00M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $10.36M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |